- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04567602
A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag (INSPECTIO)
March 26, 2024 updated by: Janssen-Cilag S.p.A.
Non-Interventional Study on Pulmonary Arterial Hypertension Patients Treated With Macitentan or Selexipag: Experience From an Italian Cohort (INSPECTIO)
The purpose of the study is to evaluate the change from baseline to 12 months after study enrollment in the number of the following non-invasive risk criteria: World Health Organization Functional Class (WHO/FC), 6-minute walk distance (6MWD), Brain Natriuretic Peptide (BNP) or N-terminal pro-brain Natriuretic Peptide (NT-proBNP).
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
186
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Acquaviva Delle Fonti, Italy, 70021
- Generale Regionale F. Miulli
-
Ancona, Italy, 60126
- A.O. Universitaria Ospedali Riuniti di Ancona
-
Bari, Italy, 70124
- Azienda Ospedaliero Universitaria Consorziale Policlinico Di Bari
-
Bari, Italy, 70131
- Ospedale Di Venere
-
Bolzano, Italy, 39100
- Ospedale di Bolzano
-
Brescia, Italy, 25123
- ASST Spedali Civili Brescia
-
Cagliari, Italy, 09134
- Azienda Ospedaliera G. Brotzu
-
Catanzaro, Italy, 88100
- AO di Catanzaro Pugliese Ciaccio
-
Chieti, Italy, 66100
- ASL2 Lanciano - Vasto - Chieti - Ospedale 'SS Annunziata' di Chieti
-
Firenze, Italy, 50134
- AOU Careggi
-
Foggia, Italy, 71122
- Azienda Ospedaliero Universitaria Ospedali Riuniti Di Foggia
-
Genova, Italy, 16132
- Ospedale Policlinico San Martino IRCCS
-
Ivrea, Italy, 10015
- Presidio Ospedaliero di Ivrea
-
Macerata, Italy, 62100
- UOC Oncologia Ospedale Provinciale di Macerata
-
Milano, Italy, 20132
- IRCCS Ospedale San Raffaele
-
Milano, Italy, 20122
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
-
Milano, Italy, 20138
- Centro Cardiologico Monzino
-
Napoli, Italy, 80131
- Ospedale Monaldi
-
Novara, Italy, 28100
- Università del Piemonte Orientale - Ospedale Maggiore della Carità di Novara
-
Padova, Italy, 35128
- AOU di Padova
-
Palermo, Italy, 90127
- ISMETT Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione
-
Pavia, Italy, 27100
- Fondazione IRCCS Policlinico San Matteo
-
Pisa, Italy, 56124
- Fondazione Toscana Gabriele Monasterio CNR
-
Roma, Italy, 00168
- Policinico A Gemelli
-
Roma, Italy, 00161
- AOU Policlinico Umberto I
-
San Donato Milanese, Italy, 20097
- IRCCS Policlinico San Donato
-
Sassari, Italy, 07100
- Presidio SS Annunziata AOU Sassari
-
Torino, Italy, 10126
- Azienda Ospedaliera Citta della Salute e della Scienza di Torino
-
Udine, Italy, 33100
- ASUI Santa Maria della Misericordia di Udine
-
Verona, Italy, 37134
- Ospedale Borgo Roma
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Study population consist of participants with confirmed diagnosis of PAH.
Description
Inclusion Criteria:
- Participants in the clinical classification of pulmonary hypertension Group 1 (PAH)
- Participants with idiopathic, heritable and associated forms of PAH (connective tissue disease, congenital heart disease corrected at least 1-year ago, human immunodeficiency virus infection, drug use or toxin, and porto-pulmonary)
- Confirmed diagnosis of PAH with hemodynamic study right heart catheterization (RHC) at enrolment or at latest follow-up (not later than twelve months from enrolment date)
- Participants with a low or intermediate mortality risk profile, as per clinical judgement based on a multiparametric approach including clinical, functional exercise, right ventricular function and hemodynamic parameters
- Participants currently in treatment with selexipag and/or macitentan (in monotherapy or in combination therapy)
Exclusion Criteria:
- Participants in Group 1 that are responders to the vasoreactivity test
- Participants with pulmonary veno-occlusive disease (PVOD), defined on the basis of the following chest findings at high-resolution computed tomography (HRCT): centrilobular ground-glass opacities, smooth thickening of interlobular septa, mediastinal lymph node enlargement
- Participants already in treatment with subcutaneous/intravenous prostanoids. Iloprost interventional (IV) (treatment of digital ulcers in systemic sclerosis [SSc] participants according to european league against rheumatism [EULAR] guidelines) is allowed
- Participants currently enrolled in an interventional study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Participants with PAH
Participants with confirmed diagnosis of pulmonary arterial hypertension (PAH) will be enrolled in the study and the data will be collected and observed to describe the application of European ESC/ERS guidelines and related 6th WSPH proceedings on risk assessment and related treatment strategy, in clinical practice.
|
There will be no specific interventions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in the Number of the Non-Invasive Low-Risk Criteria to 12 Months
Time Frame: Baseline and 12 Months
|
Change from baseline in the number of the non-invasive low-risk criteria will be assessed according to the following parameters: world health organization (WHO)/functional class (FC)- I, II, 6-minute walk distance (6MWD) greater than (>) 440 meters (m), and brain natriuretic peptide (BNP) less than (<) 50 nanogram per liter (ng/l) or N-terminal-pro-hormone brain natriuretic Peptide (NT-proBNP) <300 ng/l.
|
Baseline and 12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Improved, Stable or Worsened Risk profile from Baseline to 12 and 24 Months
Time Frame: Baseline up to 12 and 24 Months
|
Risk profile is assessed as improved, stable or worsened where improved indicates 1 or more non-invasive parameters from intermediate to low risk profile; stable indicates no change in the parameters; and worsened indicates 1 or more non-invasive parameters move from low or intermediate to intermediate or high range risk.
|
Baseline up to 12 and 24 Months
|
Change in Progression in the Number of Participants with Low/High Intermediate Risk
Time Frame: Baseline up to 24 Months
|
Change in risk profile for the low/high intermediate risk participants according to following cut-off values for low intermediate risk/high intermediate risk, respectively: (6MWD [greater than or equal to [>=] or < 300m], Peak oxygen consumption [VO2] [>= or < 50% predicted], BNP [less than or equal to [<=] or > 175 ng/l], or NT-proBNP [<= or > 850 ng/l], right atrial area [RA] [<= or > 22 centimeter [cm]] and right atrial pressure [RAP] [<= or > 11 millimeter of mercury [mmHg]] or stroke volume index (SVI) (> or <= 38 milliliter per meter square [ml/m2])).
The low intermediate risk is defined by a presence of at least three low intermediate parameters and a high intermediate risk is defined by a presence of at least three high intermediate parameters.
|
Baseline up to 24 Months
|
Change from Baseline in 6MWD
Time Frame: Baseline up to 24 Months
|
Change from baseline in 6MWD will be reported.
|
Baseline up to 24 Months
|
Change from Baseline in BNP or NT-proBNP
Time Frame: Baseline up to 24 Months
|
Change from baseline in BNP or NT-proBNP will be reported.
|
Baseline up to 24 Months
|
Change from Baseline in Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) 2.0 Risk Score up to 12 and 24 Months
Time Frame: Baseline up to 12 and 24 Months
|
The REVEAL risk calculator determines the risk status and the scores can be defined as: low risk as a score of <= 6, intermediate risk as a score of 7 or 8, and high risk as a score of >= 9 for the survival rates.
|
Baseline up to 12 and 24 Months
|
Adherence to European Society of Cardiology and European Respiratory Society (ESC/ERS) guidelines and 6th World Symposium on Pulmonary Hypertension (WSPH)
Time Frame: Up to 24 Months
|
Adherence to ESC/ERS guidelines and 6th WSPH will be reported.
|
Up to 24 Months
|
Change from Baseline in Echocardiographic Parameters
Time Frame: Baseline up to 24 Months
|
Change in echocardiographic parameters will be reported as assessed by echocardiogram.
|
Baseline up to 24 Months
|
Change from Baseline in Hemodynamic Parameters
Time Frame: Baseline up to 24 Months
|
Change in hemodynamic parameters will be reported.
|
Baseline up to 24 Months
|
Hospitalization Rate due to Worsening of PAH
Time Frame: Up to 24 Months
|
The hospitalization rate due to PAH worsening will be calculated based on the number of participants with at least one hospitalization.
The calculation of the rate will be based on the number of events over the whole follow-up time that is exposure time.
|
Up to 24 Months
|
Overall Survival (OS)
Time Frame: Up to 24 Months
|
OS is defined as the duration/time from the start of study treatment to date of death due to any cause.
|
Up to 24 Months
|
Change from Baseline in Health-Related Quality of Life (HRQoL) as Measured with Emphasis-10 Questionnaire
Time Frame: Baseline up to 24 Months
|
The emPHasis-10 is a short and easy questionnaire that consists of 10 items which address breathlessness, fatigue, control and confidence.
Each item is scored on a semantic differential six-point scale (0-5), with contrasting adjectives at each end.
A total emPHasis-10 score is derived using simple aggregation of the 10 items.
emPHasis-10 scores range from 0 to 50, higher scores indicate worse quality of life.
|
Baseline up to 24 Months
|
Change from Baseline in Participants with Narrative plots
Time Frame: Baseline and 12 Months
|
Participants will be invited to fill in two narrative plots; one at the enrollment visit and one at the month 12 visit.
|
Baseline and 12 Months
|
Change from Baseline in Caregivers with Narrative Plots
Time Frame: Baseline and 12 Months
|
Caregivers will be invited to fill in two narrative plots; one at the enrollment visit and one at the month 12 visit.
|
Baseline and 12 Months
|
Number of Participants with Adverse Events (AEs) and Adverse Drug Reactions (ADRs)
Time Frame: Up to 24 Months
|
An AE is any untoward medical occurrence in a participant enrolled in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
An ADR is defined as a response to a medicinal (investigational or non-investigational) product that is noxious and unintended.
|
Up to 24 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Janssen-Cilag S.p.A., Italy Clinical Trial, Janssen-Cilag S.p.A.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 6, 2020
Primary Completion (Actual)
January 25, 2024
Study Completion (Estimated)
March 30, 2024
Study Registration Dates
First Submitted
September 23, 2020
First Submitted That Met QC Criteria
September 23, 2020
First Posted (Actual)
September 28, 2020
Study Record Updates
Last Update Posted (Actual)
March 27, 2024
Last Update Submitted That Met QC Criteria
March 26, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR108855
- 67896049PAH4009 (Other Identifier: Janssen-Cilag S.p.A., Italy)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on PAH medication
-
BayerCompleted
-
Klinikum der Universität KölnUnknownPulmonary Artery HypertensionGermany
-
Oregon State UniversityNational Institute of Environmental Health Sciences (NIEHS); Pacific Northwest... and other collaboratorsCompleted
-
Oregon State UniversityNational Institute of Environmental Health Sciences (NIEHS); Pacific Northwest... and other collaboratorsCompleted
-
ActelionTerminatedPulmonary Arterial HypertensionUnited States, Germany, Korea, Republic of, United Kingdom, China, Canada, Netherlands, Italy, Japan, Poland, Spain, Brazil, Malaysia, Argentina, Singapore, Puerto Rico, Sweden
-
Oregon State UniversityNational Institute of Environmental Health Sciences (NIEHS); Pacific Northwest... and other collaboratorsCompleted
-
Joke WuytsAssociation of Belgian Pharmacies (APB)Completed
-
University of TennesseeKali Care; Barney's Pharmacy; Creative Care Pharmacy; Hutton Pharmacy; Mustang DrugTerminated
-
Diakonhjemmet HospitalUniversity of Oslo; Diakonhjemmet Hospital Pharmacy; Diakonhjemmet FoundationCompletedDrug-Related Side Effects and Adverse Reactions | Drug Interaction Potentiation | Medication Compliance | Remission | Medicinal Substance; Adverse EffectNorway
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); David Braley and Nancy Gordon... and other collaboratorsRecruitingPolypharmacy | Multi-morbidity | Medication Therapy ManagementCanada